Supplementary Table 1. Univariate and multivariate Cox regression analyses results for evaluating variables associated with cancer-specific survival in the entire study cohort.
| Variable | Univariate analysis | Multivariate analysis | ||||
|---|---|---|---|---|---|---|
| Unadjusted HR | 95% CI | p-value | Adjusted HR | 95% CI | p-value | |
| BMI (continuous) | 0.93 | 0.87-0.99 | 0.028 | 0.93 | 0.87-1.00 | 0.057 |
| EBL (continuous) | 1.00 | 1.000-1.0001 | <0.001 | 1.00 | 1.00-1.00 | <0.001 |
| PBT | ||||||
| Not done | ||||||
| Done | 1.47 | 0.93-2.33 | 0.095 | |||
| Pathologic tumor stage | ||||||
| Organ confined | Reference | Reference | ||||
| Extravesical | 3.66 | 2.46-5.45 | <0.001 | 1.74 | 1.09-2.78 | 0.019 |
| CIS | ||||||
| Absent | Reference | Reference | ||||
| Present | 0.57 | 0.35-0.93 | 0.025 | 0.69 | 0.41-1.17 | 0.699 |
| LVI | ||||||
| Absent | Reference | Reference | ||||
| Present | 3.64 | 2.45-5.41 | <0.001 | 2.11 | 1.32-3.37 | 0.002 |
| Perivesical margin | ||||||
| Negative | Reference | Reference | ||||
| Positive | 3.74 | 1..37-10.21 | 0.010 | 0.92 | 0.31-2.67 | 0.879 |
| Pathologic nodal stage | ||||||
| N0 | Reference | Reference | ||||
| N1 | 3.30 | 1.89-5.76 | <0.001 | 2.60 | 1.45-4.66 | 0.001 |
| N2/N3 | 5.17 | 3.31-8.08 | <0.001 | 3.87 | 2.35-6.36 | <0.001 |
| No. of removed lymph nodes (continuous) | 0.95 | 0.92-0.98 | 0.001 | 0.94 | 0.91-0.96 | <0.001 |
| NACH | ||||||
| Not done | Reference | Reference | ||||
| Done | 2.34 | 1.38-3.97 | 0.002 | 2.30 | 1.34-3.93 | 0.002 |
| ACH | ||||||
| Not done | Reference | Reference | ||||
| Done | 2.80 | 1.89-4.13 | <0.001 | 1.13 | 0.69-1.83 | 0.613 |
HR, hazard ratio; CI, confidence interval; BMI, body mass index; EBL, estimated blood loss; PBT, perioperative blood transfusion; CIS, carcinoma in situ; LVI, lymphovascular invasion; NACH, neoadjuvant chemotherapy; ACH, adjuvant chemotherapy.